Optiscan Imaging Limited develops and commercializes confocal endomicroscopes for clinical and pre-clinical applications in Australia, the United States, China, and Germany. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Optiscan Imaging's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OIL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: OIL's weekly volatility (11%) has been stable over the past year.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: OIL exceeded the Australian Medical Equipment industry which returned 9.6% over the past year.
Return vs Market: OIL exceeded the Australian Market which returned 26% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Optiscan Imaging's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StOptiscan Imaging (ASX:OIL) shareholder returns have been fantastic, earning 750% in 5 years
1 month ago | Simply Wall StWe're Not Worried About Optiscan Imaging's (ASX:OIL) Cash Burn
2 months ago | Simply Wall StWhat Type Of Shareholders Make Up Optiscan Imaging Limited's (ASX:OIL) Share Registry?
Is Optiscan Imaging undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OIL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OIL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OIL is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: OIL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OIL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OIL is overvalued based on its PB Ratio (14.5x) compared to the AU Medical Equipment industry average (4.6x).
How is Optiscan Imaging forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Optiscan Imaging has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Optiscan Imaging performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OIL is currently unprofitable.
Growing Profit Margin: OIL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OIL is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare OIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OIL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: OIL has a negative Return on Equity (-20.82%), as it is currently unprofitable.
How is Optiscan Imaging's financial position?
Financial Position Analysis
Short Term Liabilities: OIL's short term assets (A$11.0M) exceed its short term liabilities (A$973.4K).
Long Term Liabilities: OIL's short term assets (A$11.0M) exceed its long term liabilities (A$506.2K).
Debt to Equity History and Analysis
Debt Level: OIL is debt free.
Reducing Debt: OIL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OIL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: OIL has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 1.8% each year
What is Optiscan Imaging current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OIL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OIL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OIL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Darren Lurie serves as Managing Director of Optiscan Imaging Ltd since April 19, 2021 and has been its Director since April 20, 2018. He had been an Executive Chairman of Optiscan Imaging Ltd since May...
CEO Compensation Analysis
Compensation vs Market: Darren's total compensation ($USD396.27K) is above average for companies of similar size in the Australian market ($USD276.85K).
Compensation vs Earnings: Darren's compensation has increased whilst the company is unprofitable.
Experienced Board: OIL's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.4%.
Optiscan Imaging Limited's company bio, employee growth, exchange listings and data sources
- Name: Optiscan Imaging Limited
- Ticker: OIL
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$142.183m
- Shares outstanding: 618.19m
- Website: https://www.optiscan.com
- Optiscan Imaging Limited
- 16 Miles Street
Optiscan Imaging Limited develops and commercializes confocal endomicroscopes for clinical and pre-clinical applications in Australia, the United States, China, and Germany. It offers FIVE2 (ViewnVivo) sys...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/21 08:06|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.